US SB2512 | 2015-2016 | 114th Congress
Status
Completed Legislative Action
Spectrum: Slight Partisan Bill (Democrat 8-4)
Status: Passed on April 19 2016 - 100% progression
Action: 2016-04-19 - Became Public Law No: 114-146. (TXT | PDF)
Text: Latest bill text (Enrolled) [PDF]
Spectrum: Slight Partisan Bill (Democrat 8-4)
Status: Passed on April 19 2016 - 100% progression
Action: 2016-04-19 - Became Public Law No: 114-146. (TXT | PDF)
Text: Latest bill text (Enrolled) [PDF]
Summary
Adding Zika Virus to the FDA Priority Review Voucher Program Act (Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to add Zika virus disease to the list of tropical diseases under the priority review voucher program, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.) The bill makes a technical correction to the tropical disease list to refer to filovirus disease, a condition caused by the family of viruses that includes the Ebola virus, instead of the family of viruses.
Title
Adding Zika Virus to the FDA Priority Review Voucher Program Act
Sponsors
Sen. Al Franken [D-MN] | Sen. Bill Nelson [D-FL] | Sen. Johnny Isakson [R-GA] | Sen. Sherrod Brown [D-OH] |
Sen. Robert Menendez [D-NJ] | Sen. Mark Kirk [R-IL] | Sen. Robert Casey [D-PA] | Sen. Rob Portman [R-OH] |
Sen. Christopher Murphy [D-CT] | Sen. Amy Klobuchar [D-MN] | Sen. Patty Murray [D-WA] | Sen. Lamar Alexander [R-TN] |
History
Date | Chamber | Action |
---|---|---|
2016-04-19 | House | Became Public Law No: 114-146. (TXT | PDF) |
2016-04-19 | House | Signed by President. |
2016-04-14 | House | Presented to President. |
2016-04-12 | House | Motion to reconsider laid on the table Agreed to without objection. |
2016-04-12 | House | On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H1602) |
2016-04-12 | House | DEBATE - The House proceeded with forty minutes of debate on S. 2512. |
2016-04-12 | House | Considered under suspension of the rules. (consideration: CR H1602-1605) |
2016-04-12 | House | Mrs. Brooks (IN) moved to suspend the rules and pass the bill. |
2016-03-25 | House | Referred to the Subcommittee on Health. |
2016-03-21 | House | Referred to the House Committee on Energy and Commerce. |
2016-03-21 | House | Received in the House. |
2016-03-18 | Senate | Message on Senate action sent to the House. |
2016-03-17 | Senate | Passed Senate with an amendment by Unanimous Consent. (consideration: CR S1606-1607; text as passed Senate: CR S1606) |
2016-03-15 | Senate | Placed on Senate Legislative Calendar under General Orders. Calendar No. 389. |
2016-03-15 | Senate | Committee on Health, Education, Labor, and Pensions. Reported by Senator Alexander with an amendment in the nature of a substitute. Without written report. |
2016-03-09 | Senate | Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably. |
2016-02-08 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
Same As/Similar To
HB4400 (Same As) 2016-02-05 - Referred to the Subcommittee on Health.
Subjects
Drug safety, medical device, and laboratory regulation
Drug therapy
Health
Infectious and parasitic diseases
Drug therapy
Health
Infectious and parasitic diseases